HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Schucker, J. J. Articles by Ward, K. E. Search for Related Content PubMed PubMed Citation Articles by Schucker, J. J. Articles by Ward, K. E.

JASON J. SCHUCKER, PHARM.D., is Community Pharmacist, Hannaford Pharmacy, Waterboro, ME; at the time of writing, he was a Pharm.D. degree candidate at the University of Rhode Island College of Pharmacy, Kingston. KRISTINA E. WARD, PHARM.D., is Clinical Assistant Professor and Director, Drug Information Services, College of Pharmacy, University of Rhode Island, Kingston.

Address correspondence to Dr. Ward at the College of Pharmacy, University of Rhode Island, 201A Fogarty Hall, Kingston, RI 02881 (kward{at}uri.edu).

Purpose. The pathophysiology of hyperphosphatemia associated with end-stage renal disease and treatment with phosphate binders are discussed. Summary. Phosphorus is an essential element necessary for the normal function of the human body, required for skeletal construction and synthesis of DNA, proteins, and adenosine triphosphate. In healthy individuals, serum phosphorus concentrations are maintained between 2.5 and 4.5 mg/dL through diet and renal excretion. In renal insufficiency, phosphorus excretion declines and hyperphosphatemia develops. The body’s compensation mechanisms cause secondary hyperparathyroidism and renal osteodystrophy. Phosphate binders provide an effective means for managing serum phosphate. Commercially available phosphate binders include calcium carbonate, calcium acetate, sevelamer, lanthanum, and, rarely, aluminum hydroxide. Because of aluminum’s known toxicities, aluminum-based phosphate binders have a limited place in therapy. Calcium carbonate’s benefits are seen over a narrow gastric pH range, thereby limiting the drug’s utility. Calcium acetate is effective over a wide pH range. Other phosphate binders, including sevelamer hydrochloride and lanthanum carbonate, have recently entered the market, but their use remains controversial. Conclusion. If left untreated, hyperphosphatemia can result in secondary hyperparathyroidism, renal osteodystrophy, and metastatic calcification of blood vessels and soft tissue. The treatment of hyperphosphatemia in patients with chronic renal failure includes dialysis, dietary phosphorus restrictions, phosphate-binding medications, and vitamin D analogs. Selection of phosphate binders should be based on patient characteristics, including serum phosphate, serum calcium, and intact parathyroid hormone concentrations, and patient tolerability. Index terms: Aluminum hydroxide; Calcium acetate; Calcium carbonate; Dialysis; Hyperphosphatemia; Kidney failure; Lanthanum carbonate; Phosphate binders; Sevelamer hydrochloride; Toxicity; Vitamin D derivatives